The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
Ours is a story of India’s resilient public health system and of everyone working together as team India to battle the pandemic
Rabies claims around 59,000 deaths globally a year, of which around 20,000 or just over one-third of the deaths take place in India alone
Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial
The Prime Minister addressed a major problem that is affecting the income of farmers which is the diseases of animals and emphasised that in this direction India is working towards universal vaccination of animals
Japan’s Ministry of Health, Labour and Welfare (MHLW) has recently approved AstraZeneca's long-acting antibody combination “Evusheld” for the prevention ) and treatment of COVID-19.
iNCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy
CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccine
Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)
Subscribe To Our Newsletter & Stay Updated
